
MGC Pharmaceuticals Ltd
ASX:MXC

Fundamental Analysis


Revenue & Expenses Breakdown
MGC Pharmaceuticals Ltd
Balance Sheet Decomposition
MGC Pharmaceuticals Ltd
Current Assets | 9.4m |
Cash & Short-Term Investments | 6.5m |
Receivables | 531.3k |
Other Current Assets | 2.4m |
Non-Current Assets | 8m |
Long-Term Investments | 1.3m |
PP&E | 6.7m |
Free Cash Flow Analysis
MGC Pharmaceuticals Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
MGC Pharmaceuticals Ltd
Revenue
|
1.3m
AUD
|
Cost of Revenue
|
-1m
AUD
|
Gross Profit
|
289.6k
AUD
|
Operating Expenses
|
-15.8m
AUD
|
Operating Income
|
-15.5m
AUD
|
Other Expenses
|
-1.5m
AUD
|
Net Income
|
-17m
AUD
|
MXC Profitability Score
Profitability Due Diligence
MGC Pharmaceuticals Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Score
MGC Pharmaceuticals Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
MXC Solvency Score
Solvency Due Diligence
MGC Pharmaceuticals Ltd's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Score
MGC Pharmaceuticals Ltd's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MXC Price Targets Summary
MGC Pharmaceuticals Ltd
Dividends
Current shareholder yield for MXC is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?